东阿阿胶股份有限公司 董事会审计委员会对会计师事务所 2024 年度履职情况评估 及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》和东阿阿胶股份有限公司 （以下简称"公司"）的《公司章程》《董事会审计委员会实施细则》等规定和要 求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。 现将董事会审计委员会对会计师事务所 2024 年度履职评估及履行监督职责 的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 毕马威华振会计师事务所（以下简称"毕马威华振"）于 1992 年 8 月 18 日 在北京成立，于 2012 年 7 月 5 日获财政部批准转制为特殊普通合伙的合伙制企 业，更名为毕马威华振会计师事务所（特殊普通合伙），2012 年 7 月 10 日取得 工商营业执照，并于 2012 年 8 月 1 日正式运营。 毕马威华振总所位于北京，注册地址为北京市东城区东长安街 1 号东方广场 东 2 座办 ...

一、重要声明 东阿阿胶股份有限公司 2024 年度内部控制评价报告 东阿阿胶股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合东阿阿胶股份有限公司（以下简称 公司）内部控制管理制度，在内部控制日常监督和专项监督的基础上，内部控制 评价机构对公司 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制有 效性进行了评价。 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导公司内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变 ...

2025 年度日常关联交易预计公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-16 东阿阿胶股份有限公司 重要内容提示： 联交易额不超过 107,213 万元人民币，2024 年实际发生额为 78,456 万元人民币。 （二）预计日常关联交易类别和金额 预计 2025 年本公司及子公司与关联方发生的与日常经营相关联的交易总额， 不超过 107,233 万元人民币。截至 2025 年 1 月，已发生日常关联交易总金额为 12,380 万元人民币。 一、日常关联交易基本情况 （一）日常关联交易概述 2025 年 3 月 14 日，公司第十一届董事会第七次会议，以 7 票同意、0 票反 对、0 票弃权的表决结果，审议通过了《关于预计 2025 年度日常关联交易额的 议案》，关联董事王小跃女士对本项议案进行了回避表决。 预计 2025 年本公司及子公司与关联方发生的与日常经营相关联的交易总额 不超过 107,233 万元人民币。截至 2025 年 1 月，已发生日常关联交易总金额为 12,380 万 ...

东阿阿胶股份有限公司 2024 年度监事会工作报告 2024 年，公司监事会根据《公司法》《证券法》及《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等法律法规要求，结合实际情况，遵循《公司章 程》《监事会议事规则》等相关制度，认真履行监督职责，对 公司生产经营活动、重大事项、财务状况以及公司董事、高 级管理人员履行职责情况等进行监督，确保公司规范运作。 现将监事会 2024 年度主要工作，报告如下： 一、监事会会议召开情况 2024 年度，公司共召开 7 次监事会，审议通过了 20 项 议案，会议的召开和表决程序均符合《公司法》《公司章程》 等有关规定，会议决议公告均在公司指定信息披露媒体予以 披露。具体情况如下： （1）2024 年 3 月 20 日，召开第十届监事会第十四次会 议，审议通过了《关于 2023 年年度报告及摘要的议案》《关 于 2023 年度监事会工作报告的议案》《关于 2023 年度财务 决算及 2024 年财务预算报告的议案》《关于 2023 年度利润 分配预案的议案》《关于追认 2023 年度日常关联交易额的议 案》《关于预计 2024 年度日常关联交易额 ...

为积极践行以投资者运营为中心的发展理念，切实维护公司全体股东利益， 着力提升上市公司高质量发展水平，公司已于 2024 年 8 月 31 日披露《关于质量 回报双提升行动方案的公告》（公告编号：2024-47）。 2024 年，公司围绕"增长·质量"关键主题，以汇聚新质生产力为着力点， 深度践行"质量回报双提升"行动方案，主要体现在深耕阿胶产业主业，搭建滋 补健康新格局；夯实法人治理基础，高效提升规范运作水平；集聚创新发展动能， 汇聚新质生产力；精准合规信息披露，积极顺畅资本市场沟通渠道；坚持以投资 者为本，不断增强投资者获得感等方面。 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-18 东阿阿胶股份有限公司 关于"质量回报双提升"行动方案的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 董 事 会 二〇二五年三月十八日 股为基数，向全体股东每 10 股派发现金红利人民币 12.70 元（含税），现金红利 总额约为人民币 8.18 亿元，占 2024 年当年尚未分配归属于上市公司股东净利润 的 99.70%。 未来，东阿阿胶将坚定以 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-12 东阿阿胶股份有限公司 第十一届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届监事会第六次会 议，于 2025 年 3 月 4 日以邮件方式发出会议通知。 2．本次监事会会议，于 2025 年 3 月 14 日以现场会议方式召开。 3．会议应出席会议监事 5 人，实际出席会议监事 5 人。 4．本次监事会会议，由监事会主席周娇女士主持。 5．本次监事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、监事会会议审议情况 本次会议审议并通过了以下议案： 经审议，公司《2024 年年度报告全文及其摘要》的编制，符合法律法规、 中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了 公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 公司《2024 年年度报告全文及其摘要》是按照中国证监会和深圳证券交易 所颁发的信息披露内容与格式准则等有关 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-11 东阿阿胶股份有限公司 第十一届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东阿阿胶股份有限公司（以下简称"东阿阿胶"或"公司"）第十一届 董事会第七次会议，于 2025 年 3 月 4 日以邮件方式发出会议通知。 2.本次董事会会议，于 2025 年 3 月 14 日以现场会议方式召开。 3.会议应出席会议董事 8 人，实际出席会议董事 8 人。 4.本次董事会会议由董事长程杰主持，公司监事、高管列席了本次会议。 5.本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 经与会董事认真讨论，本次会议审议并通过了以下议案： 1.《关于 2024 年度总裁工作报告的议案》 2024 年，东阿阿胶深度践行"价值重塑、业务重塑、组织重塑、精神重塑"， 坚定落地落实"1238"战略，经营业绩稳步提升。全年营业收入同比增长 25.57%； 归属于上市公司股东的净利润同比增长 35.29%。 ...

2025 年 3 月 14 日，东阿阿胶股份有限公司（以下简称"公司"）第十一届 董事会第七次会议，以 8 票同意、0 票反对、0 票弃权的表决结果，审议通过了 《关于 2024 年度利润分配预案的议案》。 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-15 东阿阿胶股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 1．公司本次 2024 年度利润分配预案为：以 643,976,824 股为基数，向全体 股东每 10 股派发现金红利 12.70 元（含税），送红股 0 股（含税），不以公积金 转增股本。 本次利润分配方案实施时，如享有利润分配权的股份总额发生变动，则以实 施分配方案时股权登记日的享有利润分配权的股份总额为基数，按照分配总额不 变的原则对每股分红金额进行调整。 2．公司利润分配预案不触及《深圳证券交易所股票上市规则》第 9.8.1 条 规定的可能被实施其他风险警示情形。 一、审议程序 本项议案，尚需提交公司年度股东大会审议。 二、利润分配预案的基本情况 （一）本次利 ...

Financial Performance - The company's operating revenue for 2024 reached ¥5,920,785,955.41, representing a 25.57% increase compared to ¥4,715,265,729.50 in 2023[19] - Net profit attributable to shareholders was ¥1,557,000,775.65, a 35.29% increase from ¥1,150,878,550.46 in the previous year[19] - The net profit after deducting non-recurring gains and losses was ¥1,441,714,437.09, up 33.17% from ¥1,082,628,480.93 in 2023[19] - The basic earnings per share increased to ¥2.42, a rise of 35.20% from ¥1.79 in 2023[19] - The weighted average return on equity improved to 14.60%, up from 11.12% in the previous year, marking an increase of 3.48%[19] - Total assets at the end of 2024 were ¥13,087,136,728.33, a decrease of 1.65% from ¥13,306,306,533.41 at the end of 2023[19] - The net assets attributable to shareholders decreased by 3.81% to ¥10,310,173,764.03 from ¥10,719,014,633.60 in 2023[19] - The cash flow from operating activities was ¥2,170,810,025.93, reflecting an 11.13% increase compared to ¥1,953,438,009.50 in 2023[19] Dividend Distribution - The company plans to distribute a cash dividend of ¥12.70 per 10 shares, based on a total of 643,976,824 shares[5] - The profit distribution plan for 2024 proposes a cash dividend of 12.70 RMB per 10 shares, totaling approximately 818 million RMB, representing 99.70% of the undistributed net profit for the year[83] - The total cash dividend amount, including other methods, is 893,723,011.48 CNY, representing 100% of the profit distribution total[129] Research and Development - R&D investment increased by 27.63% to ¥209,941,773.61 in 2024, accounting for 3.55% of operating revenue[58] - The number of R&D personnel rose to 338, a 4.64% increase from 2023, with a notable 31.46% increase in master's degree holders[58] - The company is currently conducting 32 R&D projects, focusing on quality standards and evidence-based research for new product development[58] - The company has initiated 8 new drug research projects under its "dual-wheel drive" strategy, aimed at expanding its product pipeline[58] - The company is actively working on 14 projects to establish quality standards for potential high-value products, enhancing its competitive edge in the market[58] Market Strategy and Product Development - The company plans to implement the "1238" strategy to enhance its core business and drive innovation in traditional Chinese medicine[28] - The company launched new products, including "Zhuangben" brand and various health supplements targeting men's health, showcasing its commitment to product diversification[32] - The company aims to establish a demonstration base for the inheritance and innovation of traditional Chinese medicine culture, enhancing its brand recognition and cultural significance[35] - The company is focusing on expanding its product offerings and enhancing its research and development capabilities in the pharmaceutical sector[103] - The company is actively pursuing new strategies for market expansion and product innovation to enhance its competitive edge[103] Corporate Governance - The company has established a complete and independent business system, ensuring autonomy in operations and decision-making[92] - The company maintains a clear separation of assets, personnel, finance, and operations from its controlling shareholder[92] - The board of directors consists of 9 members, including 3 independent directors, meeting legal requirements[87] - The company has a dedicated financial department with an independent accounting system, ensuring no interference from the controlling shareholder[92] - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[90] Environmental Sustainability - The company has maintained compliance with environmental regulations, holding a valid pollution discharge permit until November 5, 2029[145] - Wastewater treatment facilities are in place, with two plants treating different types of wastewater, ensuring compliance with discharge standards[147] - The company reported no exceedance of pollutant discharge limits, with COD and ammonia nitrogen levels well below regulatory thresholds[146] - The company has implemented a comprehensive self-monitoring plan for wastewater and air emissions, achieving a 100% compliance rate in monitoring and reporting[148] - The company is committed to environmental sustainability, with treatment standards exceeding regulatory requirements[147] Management Changes - The company reported a significant leadership change with the appointment of Cheng Jie as President, effective January 10, 2022, and his term will end on October 22, 2024[97] - The company experienced a turnover in its board of directors, with multiple resignations including Bai Xiaosong and Cui Xingpin, effective March 2023 and August 2023 respectively[97] - The company announced the resignation of Chairman Bai Xiaosong effective October 22, 2024, due to job changes[98] - President Cheng Jie will continue to serve as the Party Secretary and a board member after resigning from the presidency on October 22, 2024[98] - The company is focusing on maintaining a stable management team, with several key positions remaining filled through 2027, which may support strategic initiatives[96] Financial Management - The company maintained a debt-to-asset ratio of 21.05% and had cash reserves of 5.015 billion RMB at the end of the year[82] - The company has no significant related party transactions during the reporting period[169] - The company has not reported any significant mergers or acquisitions during the reporting period[198] - The company has maintained a good integrity status with no significant debts or court judgments against it[168] Shareholder Information - The total number of shares is 643,976,824, with 100% being unrestricted shares[196] - The largest shareholder, China Resources Dong'a Ejiao Co., Ltd., holds 23.50% of shares, totaling 151,351,731 shares[199] - The top two shareholders, China Resources Dong'e Ejiao Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd., collectively hold 215,711,473 shares, accounting for 33.49% of the total share capital[200]

Investment Rating - The report initiates coverage with a "Buy" rating for Dong-E E-Jiao [1][8] Core Views - Dong-E E-Jiao is positioned as a leader in the health supplement industry, leveraging its strong brand and product portfolio to drive growth in both traditional and innovative health products [7][42] - The company has shown impressive financial performance, with a significant increase in revenue and net profit forecasted for the coming years, indicating robust growth potential [5][8] - The strategic focus on expanding product lines, particularly in the male health supplement sector, is expected to contribute positively to future earnings [7][42] Summary by Sections Company Overview - Dong-E E-Jiao, established in 1952, has evolved from a state-owned enterprise to a publicly listed company, becoming a standard-bearer in the industry [20] - The company is backed by state-owned assets, ensuring a stable shareholding structure and strategic focus on core products [22] Financial Performance - Revenue for 2024 is projected at 5,775 million yuan, with a year-on-year growth rate of 22.5% [5] - Net profit for 2024 is expected to reach 1,540 million yuan, reflecting a growth rate of 33.8% [5] - The company has maintained a gross margin of around 72.9% for 2024, indicating strong profitability [5] Product Strategy - The core product, E-Jiao blocks, maintains a market share of over 50%, supported by strong brand loyalty and digital marketing efforts [51][53] - The introduction of new health products under the "Royal Enclosure 1619" brand aims to capture the male health supplement market, further diversifying the product portfolio [7][42] - The "Compound E-Jiao Syrup" has seen a significant sales increase, with a 58.1% year-on-year growth in 2023, driven by favorable policy changes [62] Market Position - E-Jiao ranks first in sales among traditional Chinese medicine products, with a market value exceeding 60 billion yuan [45][47] - The overall market for health supplements has grown significantly, with a compound annual growth rate of 12.7% from 2020 to 2023 [47] Valuation - The report estimates a reasonable market capitalization of 482 billion yuan for 2025, indicating a potential upside of 29% from the current market value of 373 billion yuan [8]